Shanghai Hile Bio-Technology Co., Ltd. Provides Preliminary Earnings Guidance for the Year 2018
January 28, 2019
Share
Shanghai Hile Bio-Technology Co., Ltd. provided preliminary earnings guidance for the year 2018. The Company predicts that the net profit belonging to shareholders of the listed company in 2018 will be between RMB 28 million and RMB 50 million, with a decrease of between 56.04% and 75.38% compared with the same period of the year before. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 19 million and RMB 33 million, with a decrease of between 57.45% and 76.22% compared with the same period of the year before.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.